{"id":5605,"date":"2018-04-16T17:03:09","date_gmt":"2018-04-16T21:03:09","guid":{"rendered":"http:\/\/business.financialpost.com\/?p=1576188"},"modified":"2018-04-16T17:03:09","modified_gmt":"2018-04-16T21:03:09","slug":"aphria-profits-up-on-liberty-health-sale-while-u-s-cannabis-prospects-improve","status":"publish","type":"post","link":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/2018\/04\/16\/aphria-profits-up-on-liberty-health-sale-while-u-s-cannabis-prospects-improve\/","title":{"rendered":"Aphria profits up on Liberty Health sale, while U.S. cannabis prospects improve"},"content":{"rendered":"<p><span style=\"font-weight:400;\">Aphria Inc.\u2019s third-quarter income nearly tripled year-over-year, in a busy three months that saw the cannabis company begin to sell its U.S. assets and acquire smaller licensed producer Broken Coast Cannabis Inc. <\/span><\/p>\n<p><span style=\"font-weight:400;\">On Monday, the Leamington, Ont.-based medical marijuana grower announced third quarter net income of $12.95 million or 8 cents a share, compared with $4.95 million or 4 cents a share the year before. <\/span><\/p>\n<p><span style=\"font-weight:400;\">The increase was due, in large part, to a $26.3 million gain realized on the sale of Liberty Health Science Inc. shares. <\/span><\/p>\n<p><span style=\"font-weight:400;\">Aphria, which still owns 28 per cent of the U.S.-focused marijuana company, began selling its Liberty Health shares after the TMX Group Ltd. came out against TSX-listed cannabis companies operating in the U.S. &nbsp;&nbsp;<\/span><\/p>\n<p><span style=\"font-weight:400;\">Quarterly profit also got a boost from growth in revenue, which doubled year-over-year, to $10.3 million from $5.1 million.<\/span><\/p>\n<p><span style=\"font-weight:400;\">&#8220;This includes $1.1 million from Broken Coast during the month of February, the first month of our ownership,&#8221; Carl Merton, Aphria&#8217;s chief financial officer, said on a call with analysts. Aphria acquired the boutique B.C. grower in January for roughly $230 million, mostly in shares. <\/span><\/p>\n<p><span style=\"font-weight:400;\">New medical patients also drove revenue growth, with Aphria selling around 270,000 gram equivalents (of dried bud and oil) to patients on-boarded in the third quarter. <\/span><\/p>\n<p><span style=\"font-weight:400;\">Retail prices were up, with the average gram selling for $8.30 compared with $8.10 in the previous quarter (wholesale excluded). Meanwhile, \u201call-in cost of sales\u201d declined to $1.56 a gram from $2.13 in the second quarter.<\/span><\/p>\n<p><span style=\"font-weight:400;\">While the company sold 445 kilograms to other licensed producers in the three months leading up to Feb. 28, the quarter marked a turning point in Aphria\u2019s strategy, chief executive Vic Neufeld said on the analyst call. <\/span><\/p>\n<p><span style=\"font-weight:400;\">Aphria will no longer sell marijuana wholesale to other companies, in order to stockpile product ahead of recreational legalization, which is expected sometime in late summer or early fall. <\/span><\/p>\n<p><span style=\"font-weight:400;\">&#8220;If we don&#8217;t have 8,000 to 10,000 kilos available for the rec market in the month of September, then we will not be able to service what we are projecting to be the conservative opening order from various provincial regulators,&#8221; Neufeld said.<\/span><\/p>\n<p><span style=\"font-weight:400;\">Like other licensed producers, Aphria is racing to build new facilities or adapt existing greenhouses in expectation of recreational demand.<\/span><\/p>\n<p><span style=\"font-weight:400;\">It recently completed a 200,000-square-foot greenhouse expansion, which Neufeld said would start producing in the coming weeks. A further million square feet of greenhouse space is under construction, although it won\u2019t come online until January 2019. <\/span><\/p>\n<p><span style=\"font-weight:400;\">&#8220;We can struggle from October through January,&#8221; Neufeld said. <\/span><\/p>\n<p><span style=\"font-weight:400;\">Unlike other large companies, such as Canopy Growth Corp. or Aurora Cannabis Inc., Aphria hasn\u2019t begun to generate revenue from cannabis exports. <\/span><\/p>\n<p><span style=\"font-weight:400;\">It acquired Nuuvera Inc., which it has rebranded as Aphria International Inc., after the end of the third quarter, in an attempt to match its competitors\u2019 international scope. It\u2019s still waiting, however, on GMP certification for its facilities, which is a prerequisite for selling marijuana into Europe. <\/span><\/p>\n<p><span style=\"font-weight:400;\">Recent developments in the U.S., however, may give Aphria at least one competitive edge internationally, thanks to its investment in Liberty Health.<\/span><\/p>\n<p><span style=\"font-weight:400;\">On Friday, it was reported that U.S. President Donald Trump was considering protecting states that had already legalized marijuana from federal government intervention. <\/span><\/p>\n<p><span style=\"font-weight:400;\">&#8220;We&#8217;re very excited,\u201d said Neufeld. &#8220;This is just another advancement of getting to the position where medical cannabis in the U.S. moves to a Schedule II (drug).\u201d <\/span><\/p>\n<p><span style=\"font-weight:400;\">While Aphria has agreed sell off its stake in Liberty Health, this is happening in several stages due to Canadian Securities Exchange escrow rules. Aphria is expected to sell off another 15 per cent stake in Liberty Health in July. <\/span><\/p>\n<p><span style=\"font-weight:400;\">\u201cWill there be enough advancement between now and late July? Probably not,\u201d Neufeld said. But if Trump does take a more accepting approach to marijuana, the TMX Group \u201cwill focus more eyeballs on what&#8217;s happening in the U.S.,\u201d Neufeld said. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aphria revenues double, year-over-year, thanks to Broken Coast acquisition and new patients<\/p>\n","protected":false},"author":578,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/5605"}],"collection":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/users\/578"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/comments?post=5605"}],"version-history":[{"count":1,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/5605\/revisions"}],"predecessor-version":[{"id":5606,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/posts\/5605\/revisions\/5606"}],"wp:attachment":[{"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/media?parent=5605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/categories?post=5605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lifeinsurance-orleans.ca\/index.php\/wp-json\/wp\/v2\/tags?post=5605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}